DX3-213B
Based on 1 Customer Validation
DX3-213B is a highly potent, orally active oxidative phosphorylation (OXPHOS) complex I inhibitor (IC50=3.6 nM). DX3-213B impairs ATP generation (IC50=11 nM), and blocks MIA PaCa-2 cell growth (GI50=11 nM). DX3-213B is used for the research of the pancreatic cancer.
For research use only. We do not sell to patients.
- Purity: 99.68%
- CAS No.: 2749555-66-4
- Formula: C20H28F2N2O5S2
- Molecular Weight:478.57
-
Storage:Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month
-
Biological Activity
-
Chemical Information
-
Solvent & Solubility
- Purity & Documentation
- References
-
Help & FAQs
-
Metabolism/Protease Compound Library
HY-L012
-
Stem Cell Signaling Compound Library
HY-L017
-
Anti-Cancer Compound Library
HY-L025
-
Anti-Aging Compound Library
HY-L034
-
Reprogramming Compound Library
HY-L039
-
Orally Active Compound Library
HY-L061
-
Glutamine Metabolism Compound Library
HY-L064
-
Anti-Pancreatic Cancer Compound Library
HY-L077
-
Anti-Cancer Metabolism Compound Library
HY-L083
-
Anti-Parkinson's Disease Compound Library
HY-L085
-
Neurodegenerative Disease-related Compound Library
HY-L086
-
Mitochondria-Targeted Compound Library
HY-L089
-
Glucose Metabolism Compound Library
HY-L092
-
Cuproptosis Compound Library
HY-L133
-
Cancer Stem Cells Compound Library
HY-L135
-
Heterocyclic Compound Library
HY-L138
-
Mitochondrial Protection Compound Library
HY-L144
-
Metabolic Enzyme Compound Library
HY-L146
-
Bioactive Compound Library Max
HY-L181
-
MCE Bioactive Compound Library
HY-L001V
-
Bioactive Compound Library
HY-L001
-
Non-Alcoholic Fatty Liver Disease (NAFLD) Compound Library
HY-L199
-
High-Throughput Bioactive Compound Library
HY-L205
Biological Activity
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| BXPC-3 | IC50 |
0.05 μM
Compound: 23; DX3-213B
|
Cytotoxicity against human BXPC-3 cells assessed as inhibition of cell growth incubated for overnight in glucose-containing medium followed by compound addition and measured after 7 days by MTT assay
Cytotoxicity against human BXPC-3 cells assessed as inhibition of cell growth incubated for overnight in glucose-containing medium followed by compound addition and measured after 7 days by MTT assay
|
[PMID: 35167303] |
| MIA PaCa-2 | IC50 |
>3000 nM
Compound: 23; DX3-213B
|
Inhibition of oxidative phosphorylation in human MIA PaCa-2 cells assessed as reduction in ATP production incubated for 24 hrs in glucose-containing medium by celltiter-glo luminescence cell viability assay
Inhibition of oxidative phosphorylation in human MIA PaCa-2 cells assessed as reduction in ATP production incubated for 24 hrs in glucose-containing medium by celltiter-glo luminescence cell viability assay
|
[PMID: 35167303] |
| MIA PaCa-2 | IC50 |
0.011 μM
Compound: 23; DX3-213B
|
Cytotoxicity against human MIA PaCa-2 cells assessed as inhibition of cell growth incubated for overnight in glucose-containing medium followed by compound addition and measured after 7 days by MTT assay
Cytotoxicity against human MIA PaCa-2 cells assessed as inhibition of cell growth incubated for overnight in glucose-containing medium followed by compound addition and measured after 7 days by MTT assay
|
[PMID: 35167303] |
| MIA PaCa-2 | IC50 |
11 nM
Compound: 23; DX3-213B
|
Inhibition of oxidative phosphorylation in human MIA PaCa-2 cells assessed as reduction in ATP production incubated for 24 hrs in galactose-containing medium by celltiter-glo luminescence cell viability assay
Inhibition of oxidative phosphorylation in human MIA PaCa-2 cells assessed as reduction in ATP production incubated for 24 hrs in galactose-containing medium by celltiter-glo luminescence cell viability assay
|
[PMID: 35167303] |
| MIA PaCa-2 | IC50 |
9.1 nM
Compound: 23; DX3-213B
|
Cytotoxicity against human MIA PaCa-2 cells assessed as inhibition of cell growth incubated for overnight in galactose-containing medium followed by compound addition and measured after 3 days by MTT assay
Cytotoxicity against human MIA PaCa-2 cells assessed as inhibition of cell growth incubated for overnight in galactose-containing medium followed by compound addition and measured after 3 days by MTT assay
|
[PMID: 35167303] |
| MIA PaCa-2 | IC50 |
>3000 nM
Compound: 23; DX3-213B
|
Cytotoxicity against human MIA PaCa-2 cells assessed as inhibition of cell growth incubated for overnight in glucose-containing medium followed by compound addition and measured after 3 days by MTT assay
Cytotoxicity against human MIA PaCa-2 cells assessed as inhibition of cell growth incubated for overnight in glucose-containing medium followed by compound addition and measured after 3 days by MTT assay
|
[PMID: 35167303] |
Chemical Information
-
CAS No. 2749555-66-4
-
Appearance Solid
-
Molecular Weight 478.57
-
Formula C20H28F2N2O5S2
-
Color White to off-white
-
SMILES
O=S(N1C[C@@H](CCC1)C(N2CCC(F)(CC2)F)=O)(C3=CC=C(C=C3)S(C(C)C)(=O)=O)=O
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month
Solvent & Solubility
DMSO : 125 mg/mL (261.19 mM; ultrasonic and warming and heat to 60°C; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.08 mg/mL (4.35 mM); Clear solution
This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 2.08 mg/mL (4.35 mM); Clear solution
This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL.
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Purity & Documentation
-
Data Sheet (270 KB)
-
SDS (251 KB)
- English - EN (251 KB)
- Français - FR (251 KB)
- Deutsch - DE (251 KB)
- Norwegian - NO (251 KB)
- Español - ES (251 KB)
- Swedish - SV (251 KB)
- Italian - IT (251 KB)
- Portuguese - PT (251 KB)
-
Handling Instructions (2659 KB)
References
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 2.0896 mL | 10.4478 mL | 20.8956 mL | 52.2390 mL |
| 5 mM | 0.4179 mL | 2.0896 mL | 4.1791 mL | 10.4478 mL | |
| 10 mM | 0.2090 mL | 1.0448 mL | 2.0896 mL | 5.2239 mL | |
| 15 mM | 0.1393 mL | 0.6965 mL | 1.3930 mL | 3.4826 mL | |
| 20 mM | 0.1045 mL | 0.5224 mL | 1.0448 mL | 2.6119 mL | |
| 25 mM | 0.0836 mL | 0.4179 mL | 0.8358 mL | 2.0896 mL | |
| 30 mM | 0.0697 mL | 0.3483 mL | 0.6965 mL | 1.7413 mL | |
| 40 mM | 0.0522 mL | 0.2612 mL | 0.5224 mL | 1.3060 mL | |
| 50 mM | 0.0418 mL | 0.2090 mL | 0.4179 mL | 1.0448 mL | |
| 60 mM | 0.0348 mL | 0.1741 mL | 0.3483 mL | 0.8706 mL | |
| 80 mM | 0.0261 mL | 0.1306 mL | 0.2612 mL | 0.6530 mL | |
| 100 mM | 0.0209 mL | 0.1045 mL | 0.2090 mL | 0.5224 mL |
Powered by Bioz